Charles River Laboratories International, Inc.

As of June 30, 2026, Charles River Laboratories International, Inc. carries a market capitalization of 10.82B, placing it among publicly traded companies globally. Its enterprise value stands at 13.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Charles River Laboratories International, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Charles River Laboratories International, Inc. has 47.73M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.77, and the price-to-book ratio stands at 3.81.

As of June 30, 2026, Charles River Laboratories International, Inc. trades at an EV/EBITDA multiple of 35.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 152.08 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 13.71B versus a market cap of 10.82B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Charles River Laboratories International, Inc. maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 104.82, indicating elevated leverage, while an interest coverage ratio of 3.65 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. posted a negative return on equity (ROE) of -7.70, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.16, reflecting losses generated across the asset base. The company generates approximately 201,969.04 in revenue per employee across its workforce of 19,800.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.60 indicates how many times Charles River Laboratories International, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. recorded 52.63M in income tax expense. The company reported a pretax loss of -183.67M and -238.46M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Charles River Laboratories International, Inc.'s stock has gained approximately 81.64% over the past 52 weeks. The 50-day moving average sits at 292.66, while the 200-day moving average is 217.46.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. generated 4.00B in revenue and converted that into -238.46M in net income, yielding earnings per share of -4.83. EBITDA reached 388.03M, while operating income came in at 466.12M.

As of June 30, 2026, Charles River Laboratories International, Inc. holds 192.03M in cash and equivalents against 3.03B in total debt, resulting in a net debt position of 2.43B. Total book value stands at 2.84B, with working capital of 394.36M providing operational flexibility.

Charles River Laboratories International, Inc. produced 582.15M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. posted a gross margin of 32.67, reflecting its pricing power and cost economics. The operating margin of 11.66 and net profit margin of -5.96 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 5.25, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Charles River Laboratories International, Inc. shareholders.

As of June 30, 2026, Charles River Laboratories International, Inc. has an Altman Z-Score of 3.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.